Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Thurs Jan 9th, the US Stock Markets will be closed in observance of a national day of mourning for former President Jimmy Carter. Read the press release here. Regular trading hours will resume tomorrow.

Astrazeneca Plc ADR (AZN)

Astrazeneca Plc ADR (AZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 206,440,224
  • Shares Outstanding, K 3,100,634
  • Annual Sales, $ 45,811 M
  • Annual Income, $ 5,955 M
  • EBIT $ 9,201 M
  • EBITDA $ 14,588 M
  • 60-Month Beta 0.46
  • Price/Sales 4.07
  • Price/Cash Flow 12.35
  • Price/Book 5.06

Options Overview Details

View History
  • Implied Volatility 27.57% ( +1.78%)
  • Historical Volatility 19.12%
  • IV Percentile 90%
  • IV Rank 62.12%
  • IV High 34.77% on 10/31/24
  • IV Low 15.77% on 05/28/24
  • Put/Call Vol Ratio 1.05
  • Today's Volume 6,309
  • Volume Avg (30-Day) 8,429
  • Put/Call OI Ratio 0.64
  • Today's Open Interest 170,447
  • Open Int (30-Day) 163,897

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 1.06
  • Number of Estimates 6
  • High Estimate 1.21
  • Low Estimate 0.97
  • Prior Year 0.73
  • Growth Rate Est. (year over year) +45.21%

Price Performance

See More
Period Period Low Period High Performance
1-Month
63.75 +4.44%
on 12/20/24
69.00 -3.50%
on 12/09/24
-1.62 (-2.38%)
since 12/06/24
3-Month
62.75 +6.10%
on 11/18/24
78.65 -15.35%
on 10/16/24
-10.29 (-13.39%)
since 10/08/24
52-Week
60.47 +10.10%
on 02/12/24
87.68 -24.06%
on 08/30/24
-2.63 (-3.80%)
since 01/08/24

Most Recent Stories

More News
3 Cheap Growth Stocks to Buy in 2025

As we enter 2025, many growth stocks are trading at high valuations and could be running out of room to rise in the near term. For long-term investors, now may be a good time to reevaluate the contents...

ZM : 79.90 (-0.68%)
AZN : 66.58 (-0.09%)
UBER : 64.91 (-1.87%)
Sanofi Down 10% in 3 Months: How Should You Play the Stock?

Sanofi’s SNY stock has declined 10.2% in the past three months. However, a lot of this price decline was due to the downtrend of the overall drug and biotech sector, which performed poorly in the past...

AZN : 66.58 (-0.09%)
LLY : 787.22 (+1.80%)
ABBV : 178.50 (-0.57%)
SNY : 49.23 (-1.28%)
Better Buy: Novo Nordisk vs. AstraZeneca

Novo Nordisk (NYSE: NVO) and AstraZeneca (NASDAQ: AZN) are among the largest companies in the pharmaceutical industry. Both have generally produced strong financial results in 2024, but one wouldn't know...

AZN : 66.58 (-0.09%)
NVO : 85.64 (+2.76%)
This Penny Stock Has 270% Upside Potential in 2025. Is It a Buy Now?

Shares of this biotech company have had a rough ride in 2024, but analysts are feeling good about its future.

ALLO : 2.35 (unch)
NVDA : 140.11 (-0.02%)
IOVA : 7.17 (-3.11%)
AZN : 66.58 (-0.09%)
AMZN : 222.13 (+0.01%)
CLLS : 1.9300 (-8.10%)
The Zacks Analyst Blog Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer

For Immediate ReleasesChicago, IL – January 3, 2024 – Zacks.com announces the list of stocks and featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and...

AZN : 66.58 (-0.09%)
JNJ : 142.27 (-2.71%)
LLY : 787.22 (+1.80%)
ABBV : 178.50 (-0.57%)
PFE : 26.86 (-1.00%)
Levi & Korsinsky Reminds AstraZeneca Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 21, 2025 - AZN

New York, New York--(Newsfile Corp. - January 2, 2025) - Levi & Korsinsky, LLP notifies investors in AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) of a class action securities lawsuit.CLASS...

AZN : 66.58 (-0.09%)
5 Large Drug Stocks to Keep An Eye On in the New Year

The drug and biotech industry had a tough time in the past couple of months after Trump announced the appointment of Robert F. Kennedy Jr., a vaccine skeptic, as the head of Health and Human Services,...

AZN : 66.58 (-0.09%)
JNJ : 142.27 (-2.71%)
LLY : 787.22 (+1.80%)
ABBV : 178.50 (-0.57%)
PFE : 26.86 (-1.00%)
Is This Biotech Stock With 150% Upside a Buy Now?

The high price estimate for BridgeBio Pharma suggests potential upside of 150% in 2025.

BAYRY : 5.0600 (-1.56%)
AZN : 66.58 (-0.09%)
$SPX : 5,918.25 (unch)
BBIO : 29.45 (+2.08%)
PFE : 26.86 (-1.00%)
AZN, Daiichi Withdraw EU Filing for Dato-DXd in Nonsquamous NSCLC

AstraZeneca AZN and its Japanese partner Daiichi Sankyo announced that they have voluntarily withdrawn the marketing authorization application (MAA) for their antibody-drug conjugate (ADC), datopotamab...

AZN : 66.58 (-0.09%)
MRK : 99.85 (-1.16%)
PFE : 26.86 (-1.00%)
Pharma Stock Roundup: NVO's Obesity Study Failure, FDA Nod to PFE, LLY

This week, Novo Nordisk NVO announced disappointing data from a phase III study on a novel obesity candidate. The FDA approved Eli Lilly’s LLY Zepbound for treating moderate-to-severe obstructive sleep...

AZN : 66.58 (-0.09%)
NVO : 85.64 (+2.76%)
LLY : 787.22 (+1.80%)
PFE : 26.86 (-1.00%)
SNY : 49.23 (-1.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition...

See More

Key Turning Points

3rd Resistance Point 68.05
2nd Resistance Point 67.39
1st Resistance Point 66.99
Last Price 66.58
1st Support Level 65.93
2nd Support Level 65.27
3rd Support Level 64.87

See More

52-Week High 87.68
Fibonacci 61.8% 77.28
Fibonacci 50% 74.07
Fibonacci 38.2% 70.86
Last Price 66.58
52-Week Low 60.47

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar